A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in the Treatment of Subjects With Plasmodium Vivax Malaria
Latest Information Update: 22 Oct 2023
At a glance
- Drugs Tafenoquine (Primary) ; Chloroquine; Primaquine
- Indications Malaria
- Focus Registrational; Therapeutic Use
- Acronyms GATHER
- Sponsors GlaxoSmithKline; GSK
- 16 Jan 2019 According to a GlaxoSmithKline media release, results from DETECTIVE and GATHER studies published in The New England Journal of Medicine.
- 21 Sep 2018 According to a GlaxoSmithKline media release,Kozenis (tafenoquine) approved by the Australian Therapeutic Goods Administration for the radical cure of P. vivax malaria.Thia approval is based on the data from DETECTIVE and GATHER study.
- 10 Sep 2018 Results published in the Antimicrobial Agents and Chemotherapy